Gautam Sanyal received his Ph.D. in physical chemistry from the <em>University of Virginia. </em>Afterspending a few years in academic research and teaching positions at <em>University of Florida, MayoClinic </em>and <em>Hamilton College</em>, Gautam moved in 1989 to <em>Merck Research laboratories </em>at WestPoint, PA. He was among the first group of scientists that built protein and vaccine formulationcapabilities at <em>Merck</em>. Gautam played critical roles in delivering several candidate vaccineantigens and therapeutic proteins into clinical trials, some of which led to products such as <em>Gardasil </em>for prophylaxis against human papilloma virus. After nine productive and stimulating <em>Merck </em>years, Gautam joined <em>Astra Research Center Boston </em>as Head of Formulation andAnalytical Research. Following the merger of <em>Astra </em>and <em>Zeneca</em>, he took on Head ofBiochemistry and Protein Biophysics roles at <em>AstraZeneca Infection</em>, and was involved indiscovery of novel antibacterials. Subsequently, at <em>MedImmune</em>, Gautam led analyticsdevelopment for viruses and vaccines in pre-clinical and clinical phases. His CMC projectresponsibilities included an RSV vaccine through phase I and II clinical trials. In addition, Gautamled building of an analytical platform for development of oncolytic viruses for cancerimmunotherapy. He has extensively published research papers and review articles oncharacterization, formulation and assay development for proteins and vaccines.

Gautam retired from industry in 2017 and founded <em>Vaccine Analytics, LLC, </em>to work as an

independent consultant and is also a subject matter expert for Global Health Organizations. In addition, he is a member in the board of Directors of IABS, USA.